12-year follow-up of soft and text trials
Published 2 years ago • 944 plays • Length 3:04Download video MP4
Download video MP3
Similar videos
-
1:56
13-year follow up results of the soft and text trials in ilc
-
2:47
adjuvant endocrine therapy in premenopausal breast cancer: 12-year results from soft
-
5:19
tailorx: an update incl 12-year event rates in woman with er lymph node-negative breast cancer
-
3:50
the role of soft and text in treatment decision making for patients with breast cancer
-
7:12
determining benefit of ovarian function suppression: soft trial
-
24:33
session 9: adjuvant endocrine therapy for premenopausal women: risk stratification, type & duration
-
11:33
*exciting* what i learned when i stopped tamoxifen | hormone therapy | breast cancer journey
-
16:15
tamoxifen & aromatase inhibitors: how to tolerate them for best results!
-
12:48
my lupron side effects were life altering | hormone therapy treatment | breast cancer journey
-
10:05
gs2-05: "randomized comparison of adjuvant aromatase inhibitor exemestane (e) plus ovarian..."
-
6:14
positive: pregnancy outcome & safety of interrupting therapy for women with breast cancer
-
3:46
aphinity: 6-year follow-up results of dual her2 blockade in her2 breast cancer
-
4:02
assessment of short preoperative endocrine therapy in the adapt and adaptcycle trials
-
2:51
positive: global study to support young survivors of hr bc who desire pregnancy
-
5:44
breast cancer: adjuvant exemestane combined with ovarian function suppression better than tamoxifen
-
6:13
adjuvant exemestane more effective than tamoxifen (combined with ofs) in women with breast cancer
-
30:56
adjuvant treatment for early stage hormone positive breast cancer: role of genomic signatures
-
6:48
how to use endocrine therapy in premenopausal women with er early breast cancer
-
8:18
endocrine therapy in premenopausal women with hr breast cancer
-
1:47
an overview of the ma17r trial in breast cancer
-
3:11
ovarian function suppression in premenopausal women with breast cancer
-
3:37
comparing adjuvant tamoxifen with ovarian function suppression via exomestane to tamoxifen alone